We thank patients and their families for their interest and participation in clinical trials.
Clinical trial participation makes research and advances in the treatment of cancer and infectious diseases possible.
When you join a clinical trial, you play an active role in your own health care, you gain access to new research treatments before they are widely available, and you help others by contributing to medical research.
By participating in a clinical trial you help advance medicine and improve lives.
Our cellular immunotherapy products are universal donor and off-the-shelf by design to improve clinical access with on-demand dosing for all patients in need.
We are currently working on 3 clinical trials focused on Acute Myeloid Leukemia (AML) and COVID-19.
More than 300 product infusions to date across 5 clinical trials with no unexpected serious adverse events or infusional toxicities.
OUR CLINICAL TRIALS
An Allogeneic Natural Killer (NK) Cell Therapy, in Subjects Hospitalized for COVID-19
An Open-Label Pilot Multicenter Study to Evaluate the Safety and Efficacy of DVX201 NK Cells in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome or High Risk Overlapping Myelodysplastic / Myeloproliferative Neoplasms
INDICATION: RELAPSED/REFRACTORY AML | HIGH RISK MDS/MPN
A Multi-Center, Randomized, Controlled Trial of Standard of Care Intensive Chemotherapy ± Dilanubicel in Adults with De Novo and Treatment-Related Acute Myeloid Leukemia
INDICATION: Newly diagnosed AML
If you have questions about our clinical trials, please contact us: Clinicaltrials@deverratx.com
At Deverra, we understand how difficult it is to find reliable and credible information, therefore we are providing links to trusted and verified information about clinical trials, COVID-19, cancer, and Acute Myeloid Leukemia (AML). All content is reviewed by medical experts for accuracy.